Covid-19 Vaccine Trial From AstraZeneca, Oxford Can Resume in U.S. - The Wall Street Journal

1 month ago 35

Federal health regulators allowed the resumption of U.S. studies of a leading Covid-19 vaccine candidate from AstraZeneca PLC and the University of Oxford, according to a person familiar with the matter and materials reviewed by The Wall Street Journal.

The U.S. Food and Drug Administration wrapped up its examination of two cases of a possible neurological side effect that emerged in two people in clinical research testing the shot. The agency told AstraZeneca that the late-stage trial in the U.S. can resume, the company said...

Read Entire Article